It’s that time of the year again when we at STAT recognize the Best Biopharma CEO of the year.
Before I reveal this year’s winner, here’s a look at the deserving runners-up.
Tim Walbert, Horizon Therapeutics
The immediate reason for Walbert’s spot on the Best CEO list was Amgen’s announcement one week ago that it intends to acquire Horizon for $27.8 billion — the largest transaction in biotech this year. Big deals — especially one that almost single-handedly reverses the “biotech M&A is MIA” sentiment — always grab my attention.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
